CIK 0001830487 · Large accelerated filer
Pharvaris N.V.
Sign in to watch- Ticker
- PHVS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Netherlands
- Entity type
- other
- Phone
- 31 (0)71 203 6410
- Business address
- J.H. OORTWEG 21, 2333 CH LEIDEN, LEIDEN, Netherlands
- Former names
- Pharvaris, B.V.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $20,335,217
- in 16 filings, $4.1M under 10b5-1 plans
Net −$20,335,217. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Schikan Johannes Gerardus Christiaan Petrus −$7.0M Director sold 64% of stake
- Lu Peng −$4.7M President sold 67% of stake
- Bjork Elisabeth −$2.0M Director sold 78% of stake
- Lesage Anne −$1.9M Chief Early Development sold 40% of stake
- Abele Stefan Andreas −$1.8M Chief Technical Ops Officer sold 54% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-01 | Lu Peng Chief Medical Officer | Sale 10b5-1 | −14,023 | $30.16 | $423K | 66,226 |
| 2026-05-01 | Lu Peng Chief Medical Officer | Sale 10b5-1 | −143 | $31.00 | $4K | 66,083 |
| 2026-05-01 | Lu Peng Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −14,023 | 205,451 | ||
| 2026-05-01 | Lu Peng Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −143 | 205,308 | ||
| 2026-04-30 | Schikan Johannes Gerardus Christiaan Petrus Director | Sale 10b5-1 | −28,400 | $30.30 | $861K | 355,837 |
| 2026-04-30 | Schikan Johannes Gerardus Christiaan Petrus Director | Sale 10b5-1 | −670 | $31.03 | $21K | 355,167 |
| 2026-04-30 | Lesage Anne Chief Early Development | Option exercise 10b5-1 | +3,700 | $2.59 | $10K | 60,150 |
| 2026-04-30 | Lesage Anne Chief Early Development | Sale 10b5-1 | −3,700 | $30.26 | $112K | 56,450 |
| 2026-04-30 | Lesage Anne Chief Early Development | Option exercise 10b5-1 | +18,000 | $8.05 | $145K | 74,450 |
| 2026-04-30 | Lesage Anne Chief Early Development | Sale 10b5-1 | −18,000 | $30.26 | $545K | 56,450 |
| 2026-04-30 | Lesage Anne Chief Early Development | Sale 10b5-1 | −19,200 | $30.26 | $581K | 133,969 |
| 2026-04-30 | Lesage Anne Chief Early Development | Option exercise · Stock Option (Right to Buy) 10b5-1 | −3,700 | 9,072 | ||
| 2026-04-30 | Lesage Anne Chief Early Development | Option exercise · Stock Option (Right to Buy) 10b5-1 | −18,000 | 82,000 | ||
| 2026-04-30 | Lu Peng Chief Medical Officer | Option exercise 10b5-1 | +15,000 | $2.59 | $39K | 81,083 |
| 2026-04-30 | Lu Peng Chief Medical Officer | Sale 10b5-1 | −15,000 | $30.24 | $454K | 66,083 |
| 2026-04-30 | Lu Peng Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −15,000 | 219,474 | ||
| 2026-04-29 | Schikan Johannes Gerardus Christiaan Petrus Director | Sale 10b5-1 | −3,830 | $30.07 | $115K | 384,237 |
| 2026-04-29 | Lesage Anne Chief Early Development | Option exercise 10b5-1 | +3,700 | $2.59 | $10K | 60,150 |
| 2026-04-29 | Lesage Anne Chief Early Development | Sale 10b5-1 | −3,700 | $30.08 | $111K | 56,450 |
| 2026-04-29 | Lesage Anne Chief Early Development | Sale 10b5-1 | −3,700 | $30.06 | $111K | 153,169 |
Page 7 of 9 · 170 trades